In view of the suggested role of PACAP, but not VIP, in migraine, an antibody against the PAC1 receptor (AMG 301) has been developed for the treatment of migraine (Clinical trials identifier: NCT03238781). This evidence concerns the gene ADCYAP1R1 and migraine disorder.